Immunotherapy for cancer

ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy

3 weeks ago talkbio0Tagged Appointments, Biotechnology, CEO, Immunotherapy for cancer, Keren Leshem, Leadership, RNA-LNP, ViVac Pharma

ViVac Pharma; Keren Leshem; CEO appointment; RNA-LNP; cancer immunotherapy; leadership; biotechnology

UbiVac Showcases First ‘Dark Matter’ Cancer Immunotherapy Clinical Data at SITC 2025 Annual Meeting

4 weeks ago talkbio0Tagged Allogeneic Autophagosome-enriched Vaccine DPV-001, alternatives, anti-PD-1, Clinical Trials, Combined Modality Therapy, Dark color, dark matter, Genome, immunopeptidome, Immunotherapy for cancer, Malignant Head and Neck Neoplasm, Neoantigen, SITC, T-Cell Receptor, UbiVac

UbiVac; DPV-001; cancer immunotherapy; dark matter; dark genome; alternatives neoantigens; T cell receptor (TCR); head and neck cancer; SITC 2025; clinical trial; combination therapy; anti-PD-1; immunopeptidome

Merck Wins FDA Approval for Subcutaneous Keytruda as Exclusivity Challenges Approach

3 months ago talkbio0Tagged Approved, Biosimilars, checkpoint inhibitors, Immunotherapy for cancer, Keytruda, Keytruda Qlex, Merck, patent expiration, Solid Neoplasm, Subcutaneous Injections, United States Food and Drug Administration

Merck; Keytruda; subcutaneous injection; FDA approval; Keytruda Qlex; patent expiration; biosimilars; checkpoint inhibitors; solid tumors; cancer immunotherapy

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

6 months ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

6 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care

9 months ago talkbio0Tagged Artificial Intelligence, Biosimilars, Clinical Trial Design, Combined, Immunotherapy for cancer, Neoplasms, Personalized cancer care, Precision Medicine, targeted therapies

Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care

Merck & Co. Partners with Epitopea to Explore ‘Junk DNA’ for Novel Cancer Antigens

10 months ago talkbio0Tagged Cryptigen, CryptoMap platform, DNA, Epitopea, heroin, Immunotherapy, Immunotherapy for cancer, Merck & Co., tumor-specific antigens

Merck & Co., Epitopea, cancer immunotherapy, Cryptigen tumor-specific antigens, CryptoMap platform, junk DNA, off-the-shelf immunotherapies

I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig

11 months ago talkbio0Tagged 5'-NUCLEOTIDASE, Antibodies, Antibodies, Bispecific, Givastomig, I-Mab, Immunotherapy for cancer, metastatic gastric cancers, pipeline, reshuffle, Uliledlimab

I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers